Loading...
Market
Story
Eli Lilly's Kisunla™ for Early Symptomatic Alzheimer's Approved in Japan
Sep 24, 2024, 11:03 AM
Eli Lilly's Alzheimer's drug, Kisunla™ (donanemab-azbt), has received approval from Japan's health ministry for the treatment of early symptomatic Alzheimer's disease. This approval provides patients with another treatment option following the approval of Eisai and Biogen's Leqembi in September last year. The approval marks a significant breakthrough in the fight against dementia, with over 5 million cases projected in Japan by 2030. Eli Lilly's stock rose +0.2% pre-market following the news.
View original story
Similar markets
0-1 new treatments • 25%
2-3 new treatments • 25%
4-5 new treatments • 25%
More than 5 new treatments • 25%
None • 25%
1-2 companies • 25%
3-4 companies • 25%
More than 4 companies • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
0-1 • 25%
2-5 • 25%
6-10 • 25%
More than 10 • 25%
No new competitors • 25%
1 new competitor • 25%
2 new competitors • 25%
3 or more new competitors • 25%
None • 25%
1 • 25%
2 • 25%
3 or more • 25%
0 countries • 25%
1-5 countries • 25%
6-10 countries • 25%
More than 10 countries • 25%
More than 3 competitors • 25%
2 to 3 competitors • 25%
1 competitor • 25%
No new competitors • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
DDL-920 • 25%
Aduhelm • 25%
Leqembi • 25%
Other • 25%
Yes • 50%
No • 50%
Kisunla™ • 33%
Leqembi • 33%
Other/new drugs • 33%